放射性核素在嗜铬细胞瘤诊断与治疗中的应用进展  

Advances in the application of radionuclide in the diagnosis and treatment of pheochromocytoma

作　　者：张紫薇 程刚[1] Zhang Ziwei;Cheng Gang(Department of Nuclear Medicine,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院核医学科,400016

出　　处：《国际放射医学核医学杂志》2019年第1期82-87,共6页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：嗜铬细胞瘤(PCC)是一种罕见的神经内分泌肿瘤(NET),准确的定位诊断是进行治疗的关键。目前包括放射性碘标记的间碘苄胍(MIBG)扫描、PET、放射性核素标记的生长抑素类似物(SSTR)扫描等核医学功能显像对PCC的诊断有较高的价值。同时,放射性碘标记的MIBG及肽类受体介导的放射性核素治疗对于PCC的姑息性治疗也有一定价值。笔者对放射性核素在PCC诊断与治疗中的应用进行综述,以期为临床制定个性化治疗方案提供帮助。Pheochromocytoma(PCC) is a rare neuroendocrine tumor(NET),and accurate diagnosis is the key to treatment.At present,including radioactive iodine markers of iodine benzyl(MIBG) guanidine scanning,positron emission tomography(PET),radioactive nuclide labeled somatostatin analogue nuclear medicine functions such as scanning imaging in the diagnosis of pheochromocytoma have higher value.At the same time,the radionuclide therapy mediated by iodide and peptide receptor also has certain value in the palliative treatment of pheochromocytoma.The application of radionuclides in the diagnosis and treatment of pheochromocytoma was reviewed in order to provide help for the development of individualized treatment.

关 键 词：嗜铬细胞瘤 3-碘苄胍 正电子发射断层显像术 受体 生长抑素 治疗 显像 

分 类 号：R736.6[医药卫生—肿瘤] R730.44[医药卫生—临床医学]